Kaposi's sarcoma-associated herpesvirus (KSHV) and its roles in cancers with special emphasis on hematopoietic cancers
The latest addition to the human herpesvirus (HHV) family is KSHV, a g-2 herpesvirus (genus Rhadinovirus), which was first described in 1994. 1 KSHV is also referred to as HHV-8. KSHV has been etiologically linked to Kaposi's sarcoma (KS) and is consequently referred to as KSHV. 2 KSHV establishes latency primarily in endothelial cells (ECs) and B cells. 3, 4 KSHV is a lymphoproliferative agent that has also been implicated in several other disease conditions, namely primary effusion lymphoma (PEL, also known as body cavity-based lymphoma) and multicentric Castleman's disease (MCD). 5 There has also been inconsistent data presented concerning a role for KSHV in the progression of other malignancies such as myeloma and hemophagocytic syndrome. 5 KS is distinguished by the proliferation of multiple independent lesions of a vascular and neoplastic origin that may progress into nodular tumors localizing in the skin and visceral organs. 6 There are several clinical variations of KS that differ in aggressiveness of infection and morbidity. Classical KS is the prototype manifestation, described by Moritz Kaposi in 1872 and is a mild form observed in elderly men of European and Mediterranean descent; the other three forms of KS are 'endemic' or African KS, AIDS KS, and iatrogenic KS. Micronodular KS, a recently proposed variation of KS that mimics capillary hemangioma was observed in a human immunodeficiency (HIV)-seronegative, middle-aged Caucasian woman. 7 KS has received more attention in the wake of the AIDS pandemic as a result of its prevalence and potential for mortality in AIDS patients.
Unlike KS, PEL is a rare condition that is observed most often in individuals who are coinfected with HIV, Epstein-Barr virus (EBV), and KSHV, but instances of HIV-and EBV-seronegative individuals with PEL have also been presented in the literature. 8 PEL is characterized by the presence of malignant 'liquid'-like effusions of clonal hematopoietic cells, which arise in peritoneal, pleural, or pericardial spaces. 9 Lymphadenopathy and solid tumors are rarely observed, as the disease manifests itself primarily in body cavities (hence, body cavity-based lymphoma), but instances of extranodal soft-tissue masses have been reported. 5 These plasma cell lymphomas are further distinguished by a lack of cell lineage markers but can be recognized by the presence of monoclonal immunoglobulin rearrangements as well as a high viral DNA copy number per cell, a feature that is unique to PEL. 8, 10 MCD is another lymphoproliferative disorder similar to PEL in many ways but with key differences. MCD is diagnosed more infrequently than PEL and is characterized by the proliferation of polyclonal B cells. 10 MCD is usually localized centrally affecting lymph nodes found in the mediastinum, and can also be found in the peripheral or mesenteral lymph system. 8 In contrast to PEL, MCD is not commonly associated with EBV; in addition, only a subset of all cases are KSHV positive and are referred to as plasmablastic MCD due to the presence of large KSHV-positive plasmablasts. 3 MCD differs from PEL in other critical ways. MCD plasmablasts typically do not express constitutively high levels of CD30-like PEL lymphomas but high concentrations of cytoplasmic IgM are almost always present.
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MCD cells also do not have the characteristic immunoglobulin rearrangements found in PEL cells. Finally, MCD presents with multiple lymphadenopathy unlike PEL. 5 The importance of hematopoietic cells in both the proliferation as well as the dissemination of KSHV has not been well discussed. Interestingly, studies have expounded on this concept, demonstrating that some virally encoded proteins, such as viral G-protein-coupled receptor (vGPCR) and vIL-6, have the ability to affect hematopoiesis directly. 12 These viral proteins have homology with human genes; vGPCR most closely resembles the CXCR1 and CXCR2 chemokine receptors for human IL-8, while vIL-6 has 25% sequence homology with its human counterpart. 3, 13 Both viral analogs share similar properties of activation and function with human genes and have the ability to stimulate proliferation and angiogenesis through multiple pathways. Stromal cells in the bone marrow express particular cell surface markers, such as CD31, that interact with CD38 expressed on virally infected plasma cells instigating accumulation of tumor cells and resulting in the loss of and inhibition of bone formation. Interactions such as this may contribute to KSHV pathogenesis in other hematopoietic diseases that have been linked to KSHV such as multiple myeloma. 9 In addition, stromal cells may have an important role in homing of plasma cells to particular tissues. It has been demonstrated that stromal cell-derived growth factor-1 (SDF-1) is a chemokine released by stromal cells as well as other tissues throughout the body.
14 Recently, it has been shown that vascular endothelial growth factor (VEGF) has the ability to enhance the expression of SDF-1 in ECs and thereby aid in the dissemination of virus by recruitment of KSHV-infected cells into various sites of potential KS development. 14, 15 KSHV pathogenesis is dependent on growth factors (GF)/inflammatory cytokines(ICs)
GFs and ICs play a fundamental role in mediating several important facets of KSHV-associated pathogeneses (Table 1) . Some of these functions include the activation of ECs, recruitment and activation of lymphocytes, reactivation of KSHV, and the induction of phenotypic, and functional properties associated with the KSHV-infected, spindle-shaped cell (SSC) morphology. 11 Activation of EC and lymphocytes involves several distinct events: proliferation, differentiation, cell cycle regulation, and angiogenesis. GFs and ICs control these events by both autocrine and paracrine initiation of critical cell signaling cascades that instigate the activation of multiple transcription factors (TFs). Examples of TFs that may be activated in this way are AP-1, NFkB, and CREB ( Figure 1 ). Several ICs have been identified to be important in the growth and proliferation of KS cells in vitro. The most important ICs capable of inducing KSHV lytic replication are oncostatin M, scatter factor/hepatocyte growth factor (SF/HGF), and interferon-gamma (INF-g). 27, 53 Interestingly, IFNa has been demonstrated to inhibit lytic replication of KSHV. 62 GFs such as VEGF, basic fibroblast growth factor (bFGF), SF/ HGF, heparin-binding epidermal growth factor, placental growth factor, oncostatin-M, platelet-derived growth factor-A (PDGF-a), PDGF-b, insulin-like growth factor, and transforming growth factor-b1 all stimulate mitogenic cell growth; however, VEGF and bFGF are the critical GFs involved in the proliferation of KSHV-infected cells. 6, 37 In addition, VEGF and bFGF along with PDGF-b are known to mediate angiogenesis, which is critical for supplying blood and nutrients to areas of developing malignancy. 37 Another group of proteins that are upregulated in EC are chemokines and chemotactic factors such as MIP-1a, MIP-1b, MIP-2, MCP-1, RANTES, IL-8, GM-CSF, SDF-1, and G-CSF. These small proteins cause infiltration of KS lesions by peripheral blood mononuclear cells (PBMC) and conglomeration of lymphocytes into liquid-like effusions. This could be of great importance in the dissemination of KSHV as B cells are a natural host and reservoir and have the ability to migrate through various tissues throughout the body. Over all, KSHV replication and thus the associated pathogenesis is directly modulated by GFs and ICs. 27, 63 Figure 1
Raf plays a pivotal role in the activation of the MAPK pathway of signaling. The Raf/MEK/ERK pathway of signaling interacts with other signal transduction pathways leading to activation of a variety of TFs that are critical for the transcription of specific genes. Raf can be activated by several effector molecules. [58] [59] [60] [61] Gray colored boxes indicate molecules that are associated with the cell membranes when activated. Dotted lines denote the various divergent signaling that can activate Raf. Broken lines denote the manner in which various TFs lead to transcription of specific genes.
Characteristic features of KSHV pathogenesis
KS is still an enigma to the scientific society around the world because it is still unclear whether KS is a true neoplasm or a hyperproliferative condition. 11, 63 In the early stages, KS is thought to be a reactive process that is the result of an inflammatory response. However, late-stage KS is considered a true sarcoma due to the propensity for dissemination and metastasis. The three histological features of KS are angiogenesis, inflammation, and proliferation, all of which are essential for tumor formation. 2 The Ras/Raf/mitogen-activated protein kinase (MAPK)/ERK kinase (MEK)/extracellular signalregulated kinase (ERK) pathway regulates a variety of cellular processes, including embryogenesis, proliferation, differentiation, and apoptosis, among others, each of which plays a significant role in tumorigenesis. 64 Interestingly, constitutive activation of the components (Ras/Raf) of the MAPK pathway of signaling has been associated with a variety of tumors, including AIDS-related KS. 65 However, at this point not much research has been carried out to determine the effects of Raf-associated signaling on KSHV infection, angiogenesis, and pathogenesis.
Role for oncoprotein Raf in KSHV infection
Raf kinase (v-Raf) was first identified as an oncogene incorporated within the genomes of transforming retroviruses occurring in chickens and mice. 66 Soon after, a homologous family of genes was identified in humans. The Raf family of kinases consists of three members: B-Raf, Raf-1 (also known as c-Raf), and A-Raf. Each of these kinases is differentially expressed in various tissues and cell types and has slightly different physiological and biochemical properties. Interest in the study of Raf was sparked by the discovery that Raf is a downstream effector of Ras, an oncoprotein that is mutated in as high as 30% of human cancers. 67 In a recent groundbreaking discovery, the presence of activating mutations in Raf were identified in almost 70% of human malignant melanomas and also in about 15% of human colon cancers. 68, 69 The mutations were commonly associated with the B-Raf gene. This came as a surprise because Raf-1 was thought to be more physiologically relevant than the other isoforms due to its ubiquitous expression. However, the involvement of B-Raf in malignant human carcinoma is rational for the following reasons: firstly, recent studies have demonstrated that B-Raf is the primary effector of Ras in mediating the MAPK pathway, and secondly, it has further been shown that due to phosphorylation events, B-Raf potentially has a higher activity (approximately 10-fold higher) toward MEK than Raf-1. 70, 71 Viruses are known to activate cellular signaling pathways to enhance various stages of their replication: JC virus induces the tyrosine kinase signaling that is critical for the infection of glial cells; EGFR is a necessity for the human cytomegalovirus entry into target cells; and KSHV induces integrin-dependent FAK-Src-PI3K-rho GTPase signaling via envelope-associated gB. [72] [73] [74] Since KSHV is associated with tumors, we examined the role for oncogene Raf on virus infection. We analyzed the effect of DRaf:ER fusion proteins on infectious entry of KSHV into various target cells. 75 The DRaf:ER constructs lack both CR1 (Ras binding domain) and CR2 (negative regulating domain) domains, and the CR3 domain was fused with the hormone binding domain of estrogen receptor protein. Hence, these DRaf:ER fusion proteins become active upon b-estradiol treatment. Upon b-estradiol stimulation, DRaf:ERs specifically activate the downstream targets of the Raf molecule, MEK1/2, and ERK1/2. 76 It is therefore a good model for the investigation of the Raf/MEK/ERK signaling pathway. Using these constructs, we provided several lines of evidence to show that overexpression of Raf kinases specifically enhances KSHV infection of target cells at the level of entry (a postattachment stage). The rank order of the enhanced KSHV infection observed in target cells was directly proportional to the strength of the introduced Raf kinase: B-Raf4Raf-14A-Raf.
Raf mediates expression of GFs and ICs
Owing to its pivotal position in the MAPK pathway, Raf regulates several important cellular functions, which include cell survival, proliferation, cell cycle, cytoskeleton reorganization, angiogenesis, and differentiation. 64, 65, 76 In addition, Raf also mediates expression of a variety of GFs/ICs that play a critical role in KSHV-induced angiogenesis and pathogenesis. In turn, one interesting feature about these GFs/ICs is their ability to enhance Raf kinase activity in an autocrine or paracrine manner. Raf can be activated by more than one effector molecule due to external stimuli such as GFs, ICs, hormones, NO, and stress, for example ( Figure 1 ). The Raf-associated signaling pathway is far from being completely understood because of the complex, intricate, and well-orchestrated interactions it makes with various other signaling components, which are currently being unraveled.
In two separate studies concluded in our lab, we demonstrated the ability of Raf-induced VEGF to enhance KSHV infection of cells. 77, 78 Herein, we demonstrated the ability of VEGF to enhance KSHV entry into cells by using different molecular techniques, such as si-RNA, and transfection experiments. Our data show that VEGF is not a requirement for KSHV infection; however, VEGF plays a major role in augmenting KSHV infection of cells at a post cell-attachment stage of entry.
Effects of Raf on VEGF expression and angiogenesis
The observation that Raf oncoprotein has the ability to enhance KSHV entry into target cells has given a new dimension to analyze virus infections. The twin factors responsible for the KSHV-associated pathogenesis are hypothesized to be the microenvironment provided by the aberrant GF production and an increase in lytic cycle of KSHV infection. Similar effects of such aberrant GF production have been reported for other opportunistic virus infections in AIDS patients. 2, 6, 58 Interestingly, our recent work demonstrates the ability of oncoprotein Raf to influence these twin factors significantly. 76 At this point, the effect of GFs/ICs (other than VEGF) on KSHV infection has not been analyzed in depth. This field of study is still in its infancy.
VEGF is a pleiotropic, pro-IC ( Table 1 ) that is the product of alternative splicing and is found in at least four isotypes in humans. 79 The various isotypes are denominated according to the respective lengths of their mRNA transcripts, some of which have been shortened by the deletion of particular exons, or lengthened by repetitious additions. 80 These deletions and additions modulate the ability of VEGF to bind cell surface heparan sulfate (HS) and thereby confer differential physiological properties, as well as determine the distribution of the protein. 81 Those isotypes that contain a heparin-binding motif are generally thought to be maintained intracellularly or associated with HS on the cell surface while isotypes lacking the aforementioned motif are more likely to diffuse across the cell membrane and be found as a soluble protein in the extracellular environment. 81, 82 There are three known VEGF receptor tyrosine kinases that bind VEGF extracellularly: VEGF receptor-1 (VEGFR-1 or Flt-1), VEGF receptor-2 (VEGFR-2 or KDR), and VEGF receptor-3 Table 1 Functions of the GFs/ICs that play a major role in KSHV infection and pathogenesis
Cytokine Function
IL-1a IL-1a is a proinflammatory, pleiotropic molecule that is involved in the immune response and also plays a role in hematopoiesis. In addition, this cytokine can induce growth in an autocrine manner in several malignant cell types including leukemia and KS cells. 16, 17 IL-1b IL-1b is an important proinflammatory cytokine that also serves as a mitogen and antiapoptotic factor. IL-1b also induces the expression of many other cytokines such as IL-8 and Bcl-2. 18 Interestingly, the autocrine and paracrine effects of IL-1b serve key roles in several malignancies including KS and leukemia. 18, 19 IL-6 IL-6 is a member of an assemblage of related cytokines that share multifarious functions such as inflammation, hematopoiesis, immune regulation, and oncogenesis. IL-6 is an important molecule in the pathogenesis of several lymphomas including CD and multiple myeloma. 20 IL-8 IL-8 is a cytokine with manifold functions including cell proliferation, chemotaxis, angiogenesis, hematopoiesis, and mobilization of hematopoietic progenitor cells. 21, 22 The autocrine effects induced by this cytokine have a salient impact on the pathogenesis of several malignancies including lymphoma, melanoma, and KS. 22, 23 MCP-1 MCP-1 is a chemotactic chemokine that is capable of activating lymphocytes and monocytes, resulting in an inflammatory response that instigates monocyte and macrophage infiltration of tissues. 6, 24 Thus, MCP-1 has been imputed in the pathogenesis of a variety of human diseases. 25 
IFN-a
IFN-a is a type I interferon that is known to exhibit robust antitumor activity and is utilized in the treatment of multiple human diseases including leukemia. 26 IFN-a also inhibits lytic replication of KSHV, in vitro.
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IFN-b IFN-b is another type I interferon that is widely hailed for its inhibitory effects against chronic autoinflammatory diseases such as multiple sclerosis. 28 These effects are likely mediated via the ability of IFN-b to ablate IL-1 and TNF-a expression. 29 IFN-g IFN-g is a type II interferon that is expressed by a variety of cell types, but predominantly by T cells and large granular lymphocytes. 30 IFN-g serves to activate cells and induces autocrine and paracrine gene expression of immune regulatory proteins. 31 Thereby, IFN-g modulates many cellular events including antigen processing and presentation, antiviral activation, inhibition of proliferation, and leukocyte migration. 31 Interestingly, it has been shown that IFN-g induces lytic replication of KSHV.
TNF-a TNF-a is a proinflammatory cytokine with a variety of effects including modulation of inflammation, immune regulation, antiviral action, and autoimmunity. 32 Although it is aptly named, TNF-a could be considered a misnomer by some due to its negative role in many human diseases. Most notably and of recent characterization is its negative role in rheumatoid arthritis. TNFa has been shown to have a severe effect on T cells and the signal transduction via the TCR. 33 TNF-b TNF-b, otherwise known as lymphotoxin a/b, is homologous to TNF-a but is expressed in different cell types and has some differences in its effects. 33 One recent study has identified lymphotoxin as an autocrine growth factor in malignant EBV-infected cells. 34 TGF-b TGF-b is a multifunctional cytokine that exerts its effects primarily on endothelial cells. 35 This cytokine controls a variety of cellular events including cell replication and differentiation, migration, angiogenesis, and control of the cell cycle. TGF-b has also been implicated as a pivotal molecule in the study of malignancies due to its strong activity as a negative regulator of hematopoiesis. 36 
VEGF
VEGF is a mitogen that is required for both vasculogenesis and angiogenesis. 37 VEGF in KS development is proposed to act synergistically with bFGF in inducing angiogenesis and edema.
9,38 KS cells express VEGF and VEGF receptors (VEGFR) and use VEGF as autocrine/paracrine growth factor. 39 
HB-EGF
HB-EGF is synthesized as a type-1 transmembrane protein that can be shed enzymatically to release a soluble 14-20 kDa growth factor. 40 The transmembrane form of HB-EGF acts in a juxtacrine manner to signal neighboring cells, and as a receptor for diphtheria toxin and mediates DT-induced toxicity. 40, 41 HB-EGF is a potent mitogen and chemoattractant for many cell types. 42 HB-EGF activity is mediated via high-affinity EGF-receptor tyrosine kinases and cell surface HS via a heparin-binding domain rich in lys and arg residues. 43, 44 SDF-1 SDF-1 is a chemokine, secreted primarily by stromal cells, that acts to regulate homing of hematopoietic cells to and from a number of different tissues. 14 SDF-1 can trigger arrest of KSHV-infected cells under shear flow and can promote migration and cell adhesion, which may a critical role in KS pathogenesis.
GM-CSF
GM-CSF is a proinflammatory cytokine that is a regulator of granulocyte and macrophage cells at all stages of maturation and has the ability to initiate proliferation, differentiation, and hematopoiesis. 45 GM-CSF is therefore thought to be involved in inflammation and autoimmunity. G-CSF G-CSF is a cytokine that acts to stimulate granulopoiesis and granulocyte function. 38 The ability of this cytokine to act as an antiinflammatory agent has been utilized in treatment of human diseases such as pneumonia, leukemia, and other malignancies. 46 
PlGF
PlGF is a growth factor that is primarily involved in angiogenesis in adults, and is related to VEGF-A. 47 SF/HGF SF/HGF is a pleiotropic growth factor that stimulates angiogenesis, invasive growth, and motility in a variety of human carcinomas. 48 SF/HGF has been shown to play a role in the pathogenesis of KSHV and acts as a mitogen in KS cells. 49 PDGF PDGF is a pleiotropic growth factor that affects multiple cellular functions including growth, proliferation, angiogenesis, and differentiation by both autocrine and paracrine signaling. 50 OSM OSM is a macrophage secretory product that is a member of the IL-6 type family of cytokines. 51 Like IL-6, OSM has multiple effects including involvement in the differentiation of megakaryocytes, tumor cell growth inhibition, regulation of cholesterol metabolism, and effects on bone cells. 52 The role of OSM in inflammatory diseases has been characterized and attributed to its ability to stimulate the proteolytic pathway and induce production of inflammatory molecules resulting in tissue damage. 52 It has been shown that OSM induces lytic replication of KSHV. 53 
EGF
EGF is a mitogen that acts to stimulate proliferation primarily in fibroblasts and epithelial cells. 54 More important in the field of cancer biology are the effects mediated through EGF receptor signaling. 55 bFGF bFGF is a heparin-binding growth factor that acts synergistically with VEGF and influences cell growth, differentiation, angiogenesis, and acts as a mitogen and migration stimulant in endothelial cells. 56 bFGF has a key role in the tumorigenesis of solid tumors and has been recently linked to the pathogenesis of hematologic malignancies as well as KS. 6 The preceding list identifies the best defined of the factors currently deemed important in KSHV infection, angiogenesis, and pathogenesis but is far from exhaustive. Other molecules that play important roles in this process are virally encoded proteins (vFLIP, and homologs to bcl-2 ORF K1, ITAM ORF 16 and interferon regulatory factor ORF K9), inflammatory cytokines and chemokines (GROa, RANTES, MIP1-a, MIP-1b, and MIP-2a).
(VEGFR-3 or Flt-4). 83 Signal transduction through VEGF receptors induces the expression of a gamut of cytokines and GFs, but importantly, it also induces the expression of VEGF and VEGFR. 79, 80, 84 Thus, VEGF elicits a positive feedback loop that results in autocrine activation of cells. 85 VEGF is a multifaceted protein that has been implicated to play a paramount role in a growing number of processes including angiogenesis, proliferation, differentiation, migration, cell survival, regulation of leukocyte-mediated inflammation, activation of oncogenes, vascular development, and cell permeability. 81, 84, 85 It has been demonstrated that both VEGF and its related receptors are upregulated in tumor angiogenesis and proliferation. 39 VEGF is a factor that has been identified to be involved in all aspects of vascular development: vasculogenesis, angiogenesis, vessel recruitment, and specialized differentiation. 81 Tumor growth is often characterized by localized areas of hypoxia, a condition that leads to the upregulation of VEGF. 82 It would thus follow that vascular development is critical in the progression of carcinoma due to the increased rate of growth of tumorigenic cells. For these reasons, VEGF has become an exigent target for the treatment of human carcinomas. 85 Targeting Raf and VEGF expression as an approach to control KSHV-associated infection, angiogenesis, and pathogenesis Angiogenesis is a hallmark of KSHV-associated pathogenesis. Incidentally, both Raf and VEGF induce angiogenesis. 39, 81, 86 Angiogenesis inhibitors are currently thought to be a form of treatment with milder side effects than those generated by the use of cytotoxic anticancer drugs. 87 Some of the current It is a stabilized ribozyme directed against the pre-mRNA of the VEGF-R1 gene that is aimed at lowering the expression of the VEGF-R1 receptor. 87 This is reported to be more successful than the Bevacizumab. 88 Small molecule VEGF-R kinase inhibitors: Semaxinib (SU5416), SU6668, SU11248 (Semaxanib; Sugen/Pharmacia) These are indolinones targeted toward the VEGF-R kinase family. Both SU5416 and SU6668 were a disappointment in clinical trials. However, recently Sugen (merged with Pfizer Inc.) has started clinical trials with a third compound, SU11248, based on the indolinone template. This compound inhibits angiogenesis and tumor growth in a variety of animal models. It inhibits a wide variety of protein kinases. 88, 89 ZD6474 (AstraZeneca) This is structurally based on a quinazoline template. 90 ZD6474 has an excellent pharmacokinetics for cancer therapy and is continuing into phase III clinical studies. Vatalanib (PTK787) (Novartis/Schering AG)
It is a phthalazine derivative, which is the most selective in inhibiting VEGF-R1, VEGF-R2 and VEGF-R3. 91, 92 It is in phase III clinical trials.
Second-generation small molecule VEGF-R kinase inhibitors: AAL993, CEP-7055 (Cephalon) and CP-547,632 (OSI-Pharmaceuticals/Pfizer)
These are new drugs emerging based on a variety of chemical scaffolds. These are new generation VEGF-R2 inhibitors on which work is still in infancy.
88 
ISIS 5132
It is a 20-base antisense phosphorothioate oligodeoxyribonucleotide that specifically inhibits Raf-1 activity. This has been found to be very promising in phase II clinical trials. 96, 97 MEK PD 98059, PD 184352 (Pfizer) PD98059 and PD184532 (CI-1040) act as allosteric inhibitors: they bind outside the ATP-and ERK1/2-binding sites on MEK1/2 and modify its three-dimensional structure. This renders MEK1/2 not phosphorylatable by upstream kinases. 93 Clinically, PD184532 has been demonstrated to be well tolerated in phase I trials.
U0126 (DuPont)
Mode of action is believed to be similar to PD 98059 and PD 184352. 98, 99 However, in a recently concluded study UO126 was shown to prevent ERK activation without altering MEK phosphorylation (JGS and JAM's personal observation). ARRY-142886 (AZD6244) (AstraZeneca and Array BioPharma)
It is an orally active and selective MEK inhibitor. It has been shown to be impressive in multiple rodent models of human cancers and is being proposed as a potent second-generation MEK inhibitors.
therapeutics that inhibit the action of VEGF are described in Table 2 . [87] [88] [89] [90] [91] [92] Although targeting of specific factors may be beneficial, it should not be overlooked that cellular signaling is the crux of the dilemma. In addition, drugs targeting the signaling pathway may decrease the possibility of the development of mutations that bestow resistance. 85 On the same lines, Raf signaling is an ideal target to inhibit virus spread, infection, angiogenesis, and thus tumorigenesis, mainly because Raf occupies a pivotal position in the signaling cascade influencing production of several GFs/ICs. Some of the popular inhibitors targeting Raf-associated signaling that are presently being tested are presented in Table 3 . [93] [94] [95] [96] [97] [98] [99] We propose a combinatorial therapy involving both Raf and VEGF inhibitors to be efficacious in controlling KSHV-associated angiogenesis and pathogenesis.
Conclusions
Knowledge concerning Raf will help our understanding not only regarding the biology of KSHV-associated pathogenesis but also about other virus infections that are involved in AIDS. 58 Based on our published results, our observations, and other published works, we propose a model for KSHV-mediated pathogenesis (Figure 2) . The model takes into consideration the following facts: (1) KSHV infection is critical for the development of lesions, 100 (2) progression of a lesion to a tumor state depends upon deregulated expression of oncoproteins, 6 and (3) longlasting expression of KSHV latency genes in SSCs is critical for KS progression; SSCs make up the bulk of late-stage tumors. 2 A key feature in this model includes establishing latent infection by KSHV (Figure 2 ; step 1). Studies have indicated that both a disturbance in GF/IC expression and infection by KSHV are two major risk factors for KS development. 2, 6, 63 We propose Raf activity to play a pivotal role in KSHV-mediated pathogenesis ( Figure 2 ; step 2). Based on others and our own results, we propose Raf to also enhance the expression of GFs/ICs that play a major role in KS pathogenesis. 75, 77, 78 The most important part of our model is the autocrine/paracrine loop existing between the expression of Raf and GFs/ICs (refer Table 1 , our observation). In vivo, productive (lytic) infection is restricted to only a small number of cells at any given point of KS progression. It should be noted that only a small fraction of the cells are infected in the early-patch lesions, while the number of cells latently infected with KSHV increases with advancement of lesions, especially in late-nodular lesions. 6, 101 We hypothesize Raf to augment such a spread of KSHV to cells, as the KS lesion progresses (Figure 2; step 3a) . Overexpression of Raf plays a direct role in tumorigenesis; in addition, tumorigenesis is also mediated indirectly by the Raf-induced GFs/ICs (Figure 2 ; step 3b).
There are several questions that need to be answered and they are as follows: (1) Does virus infection induce Raf expression in hematopoietic and other target cells? (2) Are there any mutations in Raf isoforms observed in KSHV-associated pathogenesis? (3) What are the critical aspects of Raf-associated signaling that play a major role in enhancing KSHV infection? (4) What is the effect of Raf on the expression of other GFs/ICs? (5) What is the effect of Raf on other viruses that are associated with AIDS? Such knowledge about the role of Raf in both virus infection and associated pathogenesis will aid us in better understanding the disease condition and developing new line therapies targeting the Raf-GF/IC loop in hematopoietic and nonhematopoietic malignancies. Effect of RAF-GF/IC loop on KSHV-associated pathogenesis. We hypothesize a direct role for the Raf-GF/IC loop on KSHV pathogenesis.
Step 1: KSHV infection is a requirement for KSHV-mediated pathogenesis.
Step 2: Several lines of evidence point to the fact that the lytic infection is always low and confined to a very small fraction of cells including monocytes and T cells infiltrating KS lesions. The existence of the Raf-GF/IC autocrine/paracrine loop facilitates not only the spread of KSHV (step 3a) but also in the tumor formation (step 3b) that is characterized by the appearance of the SSCs.
